In the meta-analysis by Wu et al., MPO levels were not only associated with an increased risk of cardiotoxicity, but were also a more effective indicator of response to cancer treatment compared to levels of TnI and NT-proBNP [16]. The gene discussed is MPO; the disease is cancer.